New therapeutic strategies in the management of systemic sclerosis

Bibliography

• ASSASSI S, TAN FK: Genetics of scleroderma: update on single nucleotide polymorphism analysis and microarrays. Curr. Opin. Rheumatol. (2005) 17:761-767.
   PubMedGoogle Scholar
• ARNETT FC, CHO M, CHATTERJEE S, AGUILAR MB, REVEILLE JD, MAYES MD: Familial occurrence frequencies and relative risk for systemic sclerosis (scleroderma) in three United States cohort. Arthritis Rheum. (2001) 44(6):1359-1362.
   PubMed Web of Science ®Google Scholar
• STEEN VD, MEDSGER TA JR: Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. (2000) 43(11):2437-2444.
   PubMed Web of Science ®Google Scholar
• KAHALEH BM: Vascular involvement in systemic sclerosis. Clin. Exp. Rheumatol. (2004) 22(Suppl. 33):s19-s23.
   PubMedGoogle Scholar
• HENAULT J, ROBITAILLE G, SENECAL JL, RAYMOND Y: DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of antitopoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum. (2006) 54(3):963-973.
   PubMed Web of Science ®Google Scholar
• ZHOU X, TAN FK, MILEWICZ DM, GUO X, BONA CA, ARNETT FC: Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-beta pathway to recapitulate the ‘scleroderma phenotype’. J. Immunol. (2005) 175(7):4555-4560.
   PubMed Web of Science ®Google Scholar
• BARONI SS, SANTILLO M, BEVILACQUA F et al.: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N. Engl. J. Med. (2006) 354(25):2667-2676.
   PubMed Web of Science ®Google Scholar
• LUNARDI C, DOLCINO M, PETERLANA D et al.: Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach. PLoS Med. (2006) 3(1):e2.
   PubMed Web of Science ®Google Scholar
• HU PQ, OPPENHEIM JJ, MEDSGER TA Jr, WRIGHT TM: T cell lines from systemic sclerosis patients and healthy controls recognize multiple epitopes on DNA topoisomerase I. J. Autoimmun. (2006) 26(4):258-267.
   PubMedGoogle Scholar
• SATO S, FUJIMOTO M, HASEGAWA M, TAKEHARA K: Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum. (2004) 50(6):1918-1927.
   PubMed Web of Science ®Google Scholar
• TAN FK, ZHOU X, MAYES MD et al.: Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (2006) 45(6):694-702.
   PubMedGoogle Scholar
• LAPLANTE P, RAYMOND MA, GAGNON G et al.: Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis. J. Immunol. (2005) 174(9):5740-5749.
   PubMed Web of Science ®Google Scholar
• IHN H: Scleroderma, fibroblasts, signalling, and excessive extracellular matrix. Curr. Rheumatol. Rep. (2005) 7(2):156-162.
   Google Scholar
• PANNU J, GARDNER H, SHEARSTONE JR, SMITH E, TROJANOWSKA M: Increased levels of transforming growth factor beta receptor Type I and upregulation of matrix gene program: a model of scleroderma. Arthritis Rheum. (2006) 54(9):3011-3021.
   PubMedGoogle Scholar
• LEROY EC, BLACK C, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. (1988) 15(2):202-205.
   PubMed Web of Science ®Google Scholar
• AVOUAC J, SORDET C, DEPINAY C et al.: Systemic sclerosis-associated Sjogren’s syndrome is related to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum. (2006) 54(7):2243-2249.
   PubMed Web of Science ®Google Scholar
• NAKAMURA T, HIGASHI S, TOMODA K, TSUKANO M, SUGI K: Primary biliary cirrhosis (PBC)–CREST overlap syndrome with coexistence of Sjögren’s syndrome and thyroid dysfunction. Clin. Rheumatol. (2007) 26(4):596-600.
   PubMed Web of Science ®Google Scholar
• AVOUAC J, GUERINI H, WIPFF J et al.: Radiological hand involvement in systemic sclerosis. Ann. Rheum. Dis. (2006) 65(8):1088-1092.
   PubMed Web of Science ®Google Scholar
• WOLLHEIM FA: Classification of systemic sclerosis. Visions and reality. Rheumatology (2005) 44(10):1212-1216.
   PubMed Web of Science ®Google Scholar
• VALENTINI G, DELLA ROSSA A, BOMBARDIERI S et al.: European multi-centre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indices. Ann. Rheum. Dis. (2001) 60(6):592-598.
   PubMed Web of Science ®Google Scholar
• MEDSGER TA JR, BOMBARDIERI S, CZIRJAK L et al.: Assessment of disease severity and prognosis. Clin. Exp. Rheumatol. (2003) 21(3 Suppl. 29):S42-S46.
   PubMed Web of Science ®Google Scholar
• VALENTINI G, MEDSGER TA, SILMAN AJ, BOMBARDIERI S: The assessment of the patient with systemic sclerosis. Clin. Exp. Rheum. (2003) 21(3 Suppl. 29):S1-S56.
   Google Scholar
• IOANNIDIS JP, VLACHOYIANNOPOULOS PG, HAIDICH AB et al.: Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am. J. Med. (2005) 118(1):2-10.
   PubMed Web of Science ®Google Scholar
• SCUSSEL-LONZETTI L, JOYAL F, RAYNAULD JP et al.: Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (2002) 81(2):154-167.
   PubMed Web of Science ®Google Scholar
• FERRI C, VALENTINI G, COZZI F et al.: Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSScS). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (2002) 81(2):139-153.
   PubMed Web of Science ®Google Scholar
• ALLANORE Y, KAHAN A: Treatment of systemic sclerosis. Joint Bone Spine. (2006) 73(4):363-368.
   Google Scholar
• STEEN VD: Scleroderma renal crisis. Rheum. Dis. Clin. North Am. (2003) 29(2):315-333.
   PubMed Web of Science ®Google Scholar
• DEMARCO PJ, WEISMAN MH, SEIBOLD JR et al.: Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum. (2002) 46(11):2983-2989.
   PubMed Web of Science ®Google Scholar
• PHAM PT, PHAM PC, DANOVITCH GM et al.: Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature. Am. J. Transplant. (2005) 5(10):2565-2569.
   Google Scholar
• STEEN VD, SYZD A, JOHNSON JP, GREENBERG A, MEDSGER TA Jr: Kidney disease other than renal crisis in patients with diffuse scleroderma. J. Rheumatol. (2005) 32(4):649-655.
   PubMed Web of Science ®Google Scholar
• MUKERJEE D, ST GEORGE D, COLEIRO B et al.: Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann. Rheum. Dis. (2003) 62(11):1088-1093.
   PubMed Web of Science ®Google Scholar
• HACHULLA E, GRESSIN V, GUILLEVIN L et al.: Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. (2005) 52(12):3792-3800.
   PubMed Web of Science ®Google Scholar
• WILLIAMS MH, HANDLER CE, AKRAM R et al.: Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur. Heart J. (2006) 27(12):1485-1494.
   PubMed Web of Science ®Google Scholar
• TRAD S, AMOURA Z, BEIGELMAN C et al.: Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum. (2006) 54(1):184-191.
   PubMed Web of Science ®Google Scholar
• KAWUT SM, TAICHMAN DB, ARCHER-CHICKO CL, PALEVSKY HI, KIMMEL SE: Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest (2003) 123(2):344-350.
   PubMed Web of Science ®Google Scholar
• FISHER MR, MATHAI SC, CHAMPION HC et al.: Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. (2006) 54(9):3043-3050.
   PubMed Web of Science ®Google Scholar
• WILLIAMS MH, DAS C, HANDLER CE et al.: Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart (2006) 92(7):926-932.
   PubMed Web of Science ®Google Scholar
• RUBIN LJ, MENDOZA J, HOOD M et al.: Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann. Intern. Med. (1990) 112(7):485-491.
   PubMed Web of Science ®Google Scholar
• BADESCH DB, TAPSON VF, MCGOON MD et al.: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann. Intern. Med. (2000) 132(6):425-434.
   PubMed Web of Science ®Google Scholar
• CHANNICK RN, SIMONNEAU G, SITBON O et al.: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 358(9288):1119-1123.
   PubMed Web of Science ®Google Scholar
• RUBIN LJ, BADESCH DB, BARST RJ et al.: Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2002) 346(12):896-903.
   PubMed Web of Science ®Google Scholar
• DENTON CP, HUMBERT M, RUBIN L, BLACK CM: Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann. Rheum. Dis. (2006) 65(10):1336-1340.
   PubMed Web of Science ®Google Scholar
• BARST RJ, LANGLEBEN D, FROST A et al.: Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. (2004) 169(4):441-447.
   PubMed Web of Science ®Google Scholar
• BARST RJ, LANGLEBEN D, BADESCH D et al.: Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J. Am. Coll. Cardiol. (2006) 47(10):2049-2056.
   PubMed Web of Science ®Google Scholar
• SEIBOLD JR, LANGLEBEN D, BADESCH D et al.: Sitaxsentan, a selective endothelin-a receptor antagonist, improves exercise capacity in pah associated with connective tissue disorders. The Annual European Congress of Rheumatology (EULAR). Amsterdam, the Netherlands (2006) sat 0233.
   Google Scholar
• GALIE N, GHOFRANI HA, TORBICKI A et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2005) 353(20):2148-2157.
   PubMed Web of Science ®Google Scholar
• GHOFRANI HA, SEEGER W, GRIMMINGER F: Imatinib for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. (2005) 353(13):1412-1413.
   PubMed Web of Science ®Google Scholar
• KANKI-HORIMOTO S, HORIMOTO H, MIENO S et al.: Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension. Circulation (2006) 114(1 Suppl.):I181-I185.
   PubMed Web of Science ®Google Scholar
• HUMBERT M, SITBON O, SIMONNEAU G: Drug therapy: treatment of pulmonary arterial hypertension. N. Engl. J. Med. (2004) 351(14):1425-1436.
   PubMed Web of Science ®Google Scholar
• RONDELET B, KERBAUL F, MOTTE S et al.: Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation (2003) 107(9):1329-1335.
   PubMed Web of Science ®Google Scholar
• WHITE B: Interstitial lung disease in scleroderma. Rheum. Dis. Clin. North Am. (2003) 29(2):371-390.
   PubMed Web of Science ®Google Scholar
• PLASTIRAS SC, KARADIMITRAKIS SP, ZIAKAS PD et al.: Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum. (2006) 55(4):598-602.
   PubMed Web of Science ®Google Scholar
• LAUNAY D, REMY-JARDIN M, MICHON-PASTUREL U et al.: High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J. Rheumatol. (2006) 33(9):1789-1801.
   PubMed Web of Science ®Google Scholar
• TASHKIN DP, ELASHOFF R, CLEMENTS PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. (2006) 354(25):2655-2666.
   PubMed Web of Science ®Google Scholar
• CLEMENTS PJ, FURST DE, SILVER RM et al.: Outcomes at 24-months are better for patients who received one-year of cyclophosphamide (CYC) therapy for ssc alveolitis than in those who received one-year of placebo (PBO) in the scleroderma lung study. American College of Rheumatology, Washington, USA (2006) 1252.
   Google Scholar
• KAHAN A, ALLANORE Y: Primary myocardial involvement in systemic sclerosis. Rheumatology (2006) 45(Suppl. 4):iv14-iv17.
   PubMedGoogle Scholar
• VIGNAUX O, ALLANORE Y, MEUNE C et al.: Evaluation of nifedipine efficacy on myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann. Rheum. Dis. (2005) 64(9):1268-1273.
   PubMed Web of Science ®Google Scholar
• ALLANORE Y, MEUNE C, VIGNAUX O et al.: Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study. J. Rheumatol. (2006) 33(12):2464-2469.
   PubMed Web of Science ®Google Scholar
• ROBERTS CG, HUMMERS LK, RAVICH WJ, WIGLEY FM, HUTCHINS GM: A case-controlled study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut (2006) 55(12):1697-1703.
   PubMed Web of Science ®Google Scholar
• WIPFF J, ALLANORE Y, SOUSSI F et al.: Prevalence of Barrett’s esophagus in systemic sclerosis. Arthritis Rheum. (2005) 52(9):2882-2888.
   PubMedGoogle Scholar
• DERK CT, RASHEED M, ARTLETT CM, JIMENEZ SA: A cohort study of cancer incidence in systemic sclerosis. J. Rheumatol. (2006) 33(6):1113-1116.
   PubMed Web of Science ®Google Scholar
• THOMPSON AE, SHEA B, WELCH V, FENLON D, POPE JE: Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum. (2001) 44(8):1841-1847.
   PubMed Web of Science ®Google Scholar
• WISE RA, WIGLEY FM, WHITE B et al.: Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum. (2004) 50(12):3994-4001.
   PubMedGoogle Scholar
• WIGLEY FM, SEIBOLD JR, WISE RA, MCCLOSKEY DA, DOLE WP: Intravenous iloprost treatment of Raynaud’s phenomenon and ischaemic ulcers secondary to systemic sclerosis. J. Rheumatol. (1992) 19(9):1407-1414.
   PubMed Web of Science ®Google Scholar
• WIGLEY FM, WISE RA, SEIBOLD JR et al.: Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann. Intern. Med. (1994) 120(3):199-206.
   PubMed Web of Science ®Google Scholar
• KORN JH, MAYES M, MATUCCI CERINIC M et al.: Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. (2004) 50(12):3985-3993.
   PubMed Web of Science ®Google Scholar
• SEIBOLD JR, DENTON CP, FURST DE et al.: Bosentan prevents occurrence but does not speed healing of digital ulcers in patients with systemic sclerosis. American College of Rheumatology, San Diego, USA (2005) late breaking abstract 477-L2.
   Google Scholar
• FRIES R, SHARIAT K, VON WILMOWSKY H, BOHM M: Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation (2005) 112(19):2980-2985.
   PubMed Web of Science ®Google Scholar
• POPE JE, BELLAMY N, SEIBOLD JR et al.: A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. (2001) 44(6):1351-1358.
   PubMed Web of Science ®Google Scholar
• NIHTYANOVA SI, BROUGH GM, BLACK CM, DENTON CP: Mycophenolate mofetil in diffuse cutaneous systemic sclerosis – a retrospective analysis. Rheumatology (2007) 46(3):442-445.
   PubMed Web of Science ®Google Scholar